Product Information
VYVANSE 30 MG CAPSULE is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $12.3497 per EA under NDC 59417010310. Its NADAC has been published 657 times since Nov 28, 2013.
The High Outlier badge above means this manufacturer's average price in the lisdexamfetamine dimesylate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
30 mg/1
Manufacturer
Takeda Pharmaceuticals America, Inc.NDC
59417010310
Classification
Brand
Dosage Form
CAPSULE
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
LISDEXAMFETAMINE DIMESYLATEApproval Type
New Drug (NDA)
FDA Application
NDA021977On Market Since
2/23/2007
Pharmacological Classes
Price Statistics
The NADAC for VYVANSE 30 MG CAPSULE has been published 657 times since Nov 28, 2013, and over the history we have for it it has risen 105.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $12.3497 per EA |
|---|---|
| All-time high | $12.3994 (Sep 11, 2024) |
| All-time low | $6.0012 (Nov 28, 2013) |
| 52-week high | $12.3793 |
| 52-week low | $12.3497 |
| Median price | $10.2080 |
| Average price | $9.9085 |
| Largest weekly change | +9.0% (Jan 13, 2016) |
| Weeks tracked | 657 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 5 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 5 manufacturers (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 75% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of VYVANSE 30 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for VYVANSE 30 MG CAPSULE, manufactured by Takeda Pharmaceuticals America, Inc., is $12.3497 per EA (NDC 59417010310), effective Jun 24, 2026.
How has the price of VYVANSE 30 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for VYVANSE 30 MG CAPSULE has risen 105.8%. It has been tracked across 657 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for VYVANSE 30 MG CAPSULE?
Since Nov 28, 2013, the NADAC for VYVANSE 30 MG CAPSULE has ranged from a low of $6.0012 (Nov 28, 2013) to a high of $12.3994 (Sep 11, 2024), with a median of $10.2080 per EA.
Are there cheaper alternatives to VYVANSE 30 MG CAPSULE?
Yes. 5 NADAC-published products share the same active ingredient, strength, and dosage form. The lowest-priced option, LISDEXAMFETAMINE 30 MG CAPSULE, is $3.0366 per EA — about 75% below VYVANSE 30 MG CAPSULE.
Who manufactures VYVANSE 30 MG CAPSULE?
VYVANSE 30 MG CAPSULE (NDC 59417010310) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a brand product.
Related Drugs
Same classification